Twitter Facebook LinkedIn YouTube

Latest Video

FSD Pharma Generates $7.7 Million in Proceeds and 670% ROI through Sale of Interest in Cannara Biotech

Video Platform Video Management Video Solutions Video Player

FSD Pharma Inc., a specialty, biotech pharmaceutical R&D company, focused on developing, over time, a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract and the musculoskeletal system, has sold its 12% equity interest in Cannara Biotech.

Tags: